POS1073 AXIAL PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS. SAME OR DIFFERENT? A REAL-WORLD STUDY WITH EMPHASIS ON COMORBIDITIES

Background: Axial involvement affects 25-70% of psoriatic arthritis (PsA) patients, depending on the criteria used for its definition. Efforts are underway to clarify similarities and differences between axial-PsA ankylosing spondylitis (AS). Objectives: We aimed compare, in a real-world setting, AS, terms demographic, radiologic clinical (musculoskeletal extra-articular) characteristics, with focus comorbidities. Methods: All AS (New York criteria, n=128) PsA patients (CASPAR n=78) axial who were regularly followed-up outpatients’ rheumatology clinics from two tertiary hospitals (December 2018-July 2020) included. Axial-PsA was defined when both following ever present: inflammatory symptoms radiological findings X-ray or MRI sacroiliac joints spine. The considered: sacroiliitis (unilateral ≥ grade 3 bilateral 2), corner lesions squaring vertebrae, syndesmophytes (marginal para-marginal) facet arthritis. Demographic, characteristics including comorbidities compared axial-PsA. For (Major Adverse Cardiovascular Events [MACE: combined coronary disease cerebrovascular accidents], hypertension, diabetes mellitus, dyslipidemia, depression, osteoporosis, malignancies), adjustments made relevant confounders as follows: MACE adjusted for: age, gender, smoking, duration, DM non-steroidal anti-inflammatory drugs [NSAIDs] use; depression gender duration; malignancy hypertension sex, BMI, NSAIDs use, smoking for; DM: glucocorticoids treatment; osteoporosis treatment. Statistical significance is considered p-values less than 0.05 0.1 univariate multivariate analyses, respectively. Results: younger (p=0.05) diagnosed at age (p=0.002), more frequently male (p=0.04), had lower BMI (p=0.006) they HLA-B27-positive (p=0.006). In peripheral arthritis, dactylitis nail common (p=0.001 all), contrast eye (p=0.001) bowel (p=0.004). Frequency abnormalities spine similar groups while often unilateral (p<0.001 both) Comorbidities, MACE, comparable axial-PsA, apart which frequent (Table 1. next page). Table Comorbidities. Comparison AS. OR: odds ratio, MACE: Major cardiovascular events. * reported text Comorbidities (n=79 ) (n=129 Crude OR (95%CI Adjusted p-value MACE* n (%) 4 (5.1) 6 (4.6) 0.91 (0.25-3.34) 1.73 (0.32-9.34) 0.526 Dyslipidemia 37 (46.8) 45 (34.9) 0.61 (0.34-1.07) NA 0.108 Hypertension* 27 (34.2) 24 (18.6) 0.44 (0.23-0.83) 1.11 (0.38-3.21) 0.843 Diabetes mellitus* 12 (15.2) 10 (7.7) 0.47 (0.19-1.14) 1.65 (0.43-6.29) 0.463 Depression* 19 (24.1) 16 (12.4) (0.21-0.93) 0.48 (0.22-1.07) 0.07 Osteoporosis* (3.8) 2.13 (0.57-7.98) 2.40 (0.56-10.18) 0.235 Malignancies* (2.3) 0.60 (0.12-3.06) 0.87 (0.16-4.70) 0.870 Conclusion: have certain differences. comparable, Disclosure Interests: George E. Fragoulis: None declared, Maria Pappa: Gerasimos Evangelatos: Alexios Iliopoulos: Petros Sfikakis Grant/research support from: AbbVie, Pfizer, MSD, Roche, UCB, GSK, Novartis, Tektonidou Genesis, UCB.